This Government Contract opportunity from Department Of Health And Human Services was posted on August 8, 2023. The submission period has ended. Browse the details below for market research, or find similar active opportunities.

Top

Notice of Intent to Sole Source

Awarded

16111Federal

Submission Closed03/30/2023, 12:00:00 AM UTC

Contract Overview

Solicitation details, issuing organization, response deadlines, documents, and interested companies for this government contract opportunity.

Active Opportunities Like This One

NAICS: 325412

New

DIBBS

FLUORESCEIN SODIUMFluorescein Sodium Ophthalmic Strips, USP, are procured under solicitation SPE2DP-26-T-4089 with a requirement for 2 packaging units (PG), each containing 100 individually sealed 1 mg strips. The product must comply with all technical and quality specifications outlined in the DLA Master List of Technical and Quality Requirements and adhere to Medical Marking Standard No. 1, replacing all references to MIL-STD-129. Packaging must ensure protection against damage and breakage, with commercial exterior containers suitable for safe delivery by common carrier at the lowest cost to the destination. The item has a non-extendable shelf life of 36 months and is classified as a TYPE I (CODE Q) item. Labeling must include NSN, manufacturer, CAGE code, date of manufacture, expiration or retest date, contract number, and lot number. Strict prohibitions apply to the intentional addition or direct contact of mercury or mercury compounds, except for specific exceptions such as batteries, fluorescent lamps, or specialized instruments complying with NAVSEA 5100-003D, which must include a secondary containment barrier. Suppliers must submit Safety Data Sheets and labels compliant with OSHA’s revised Hazard Communication Standard (29 C.F.R. 1910.1200), and train employees on these requirements. The product is FDA-regulated, and contracting officials must route a referral in EBS for product specialist confirmation prior to award. Delivery is FOB destination within five days, with zero variance allowed in quantity. The NSN is 6505-01-503-2390, and the place of performance is San Diego, CA.

MEDICAL SUPPLY CHAIN PHARM FSA

POSTED

DEADLINE

Supply of Haematology Calibrator KitThe contract calls for the procurement and delivery of a single haematology calibrator kit, requiring full compliance with packaging, labeling, and documentation standards, including the mandatory submission of a Safety Data Sheet. The item is intended for use in medical laboratory settings and must meet stringent regulatory and technical requirements to ensure accuracy and safety in diagnostic applications. The solicitation is issued under the NAICS code 325412, which classifies it within the pharmaceutical and medicinal preparation manufacturing sector, emphasizing precision and quality control in production. The contract is structured as a subcontract under the Department of Defense’s Medical Supply Chain, managed by the MEDICAL SUPPLY CHAIN MD SURG FSF. Performance must be fulfilled for delivery to a FPO address with ZIP code 09566-4008, indicating potential overseas or military deployment logistics. Bids must be submitted by July 20, 2026, with the solicitation originally posted on July 12, 2026, providing a limited eight-day window for responses. The procurement is part of a broader effort to maintain standardized, reliable diagnostic tools across military medical facilities, with no specific set-aside provisions indicated for small or disadvantaged businesses.

MEDICAL SUPPLY CHAIN MD SURG FSF

POSTED

DEADLINE

Supplier of PLASMA CONTROL, NORMAL LEVEL (Medical Diagnostic Reagent)The contract is for the supply of a citrated plasma control solution designed for use in coagulation testing, specifically prothrombin time (PT) and activated partial thromboplastin time (APTT) assays. The product must be fully compatible with NS 6630-01-519-3589 analyzers and meet strict performance and stability standards required for diagnostic accuracy. Cold chain logistics are mandatory throughout transportation and storage to preserve product integrity, ensuring consistent quality from manufacturing to point of use. Regulatory compliance is a core requirement, with adherence to applicable medical device and in vitro diagnostic standards expected without exception. This is a subcontract under the Medical Supply Chain MD Surg FSF, managed by the Department of Defense, with performance obligated in San Antonio, Texas, at ZIP code 78226. The solicitation was posted on July 12, 2026, and responses are due by July 20, 2026. The North American Industry Classification System code 325412 applies, indicating classification within the manufacturing of in vitro diagnostic substances. All bidders must be prepared to meet the defense supply chain’s rigorous quality, delivery, and documentation protocols, with no exceptions to compliance or timeliness.

MEDICAL SUPPLY CHAIN MD SURG FSF

POSTED

DEADLINE

Supply of DPD Total Chlorine Reagent (Chemical Manufacturing)The contract mandates the manufacture and supply of DPD Total Chlorine Reagent in powder pillow form, specifically engineered to comply with federal and military standards for packaging, labeling, shelf life, and hazard communication. The product must meet stringent quality and safety criteria to ensure consistent performance in field and laboratory environments, with all materials and processes adhering to approved military specifications. The reagent is intended for use in water quality testing applications within military and government operations, requiring reliable and secure logistics to maintain efficacy over its defined shelf life. Performance is expected to be delivered to a military logistics location identified as FPO, ZIP 96693, with all shipments coordinated through the Department of Defense’s Medical Supply Chain. The contract is structured as a subcontract under NAICS code 325412, which classifies it under chemical manufacturing, and the solicitation closes on July 20, 2026. Interested parties must respond by the deadline to be considered for award, with all compliance documentation, including safety data sheets and certification of conformance, required to accompany proposals. The procurement is part of an ongoing effort to sustain critical test reagent supply chains for defense and medical operations.

MEDICAL SUPPLY CHAIN MD SURG FSF

POSTED

DEADLINE

Medical Supply Procurement and PackagingThe contract involves the procurement, packaging, and labeling of medical supplies with a 36-month shelf life, ensuring strict adherence to MIL-STD-129 for labeling and packaging requirements and compliance with OSHA hazard communication standards for safety and handling information. All supplies must be properly documented, labeled, and packaged to meet military logistics specifications, enabling seamless integration into the Department of Defense’s supply chain. The performance location is designated as Fort Bragg with a zip code of 28310, indicating the primary delivery and distribution point for these medical items. This subcontract, released under NAICS code 325412 for pharmaceutical preparation manufacturing, has a response deadline of July 20, 2026, with the solicitation posted on July 12, 2026. The contracting authority is the Medical Supply Chain Pharm FSA under the Department of Defense, and all vendors must be prepared to meet rigorous quality, compliance, and timelines to fulfill the requirements. While no specific set-aside status is indicated, bidders are expected to align with federal procurement protocols and deliver fully compliant medical inventory that supports sustained military healthcare operations.

MEDICAL SUPPLY CHAIN PHARM FSA

POSTED

1 day ago

DEADLINE

in 7 days

General Info

Agency

Department Of Health And Human Services → CDC National Center For Immunization And Respiratory DiseasesView Agency

NAICS

325412 - Pharmaceutical Preparation ManufacturingView NAICS

Place of Performance

Set-Aside

NONE

Documents

(0)

No documents available

AI Contract Breakdown

Uniform Contract Format

No contract breakdown available.

Cannot generate Contract Breakdown because no documents were found from this contract's source.

Timeline

PhaseAwarded

PostedAug 8

Justification (J&A)

AwardedJul 14

Contract was awarded

Submission Closed

03/30/2023, 12:00:00 AM UTC

Find active opportunities like this

Start your free trial to discover similar active contracts, track opportunities, and build proposals with AI assistance.

Organization & Contact Information

AgencyDepartment Of Health And Human Services → CDC National Center For Immunization And Respiratory Diseases

Contacts1 person available

OfficeAtlanta, GA, 30333, USA

Organization / Agency

Department Of Health And Human Services → CDC National Center For Immunization And Respiratory Diseases

View Agency Profile

Office AddressAtlanta, GA, 30333, USA

Contacts

Christina McMichael

contact@example.gov

+1 (555) 000-0000

Full Description

The Centers for Disease Control and Prevention intends to award one sole source firm fixed price contract modification under contract 75D30123D16111 with Sanofi Pasteur Inc. for the addition of the ACIP recommended Nirsevimab vaccine. The National Center for Immunization and Respiratory Diseases (NCIRD) awarded multiple indefinite delivery, indefinite quantity (IDIQ) one-year contracts for the purchase of standard commercial pediatric vaccines, manufactured under a current establishment and product license issued by the U.S. Food and Drug Administration (FDA). The vaccines awarded under these contracts will be purchased for NCIRD's immunization awardees (the fifty state health departments, several large city program and current and former U.S. Territories) to support immunization programs as provided under Section 317(j) of the Public Health Service Act and VFC, as established pursuant to Section 13631of the Omnibus Budget Reconciliation Act of 1993. Orders for the vaccines on these contracts are ordered through the NCIRD electronic vaccine ordering system. The initial contracts, awarded in April 2023 were established to support public sector ACIP recommended routine vaccinations for children. The Sanofi contract will be modified to support purchase of Nirsevimab for prevention of respiratory syncytial virus (RSV) in children following CDC's Advisory Committee on Immunization Practices (ACIP) approval and accompanying VFC resolution on August 3, 2023. Nisevimab from Sanofi is the only product currently licensed for prevention of RSV in infants and Sanofi is the only manufacturer with an FDA-approved license for this product. CDC's current contract with Sanofi will be modified to include a sufficient quantity of doses required to support purchase of Nirsevimab to administer to VFC eligible newborns and infants. This contract action is for supplies or services for which the Government intends to solicit and negotiate with only one source under the authority of FAR 6.302-1 and 41 U.S.C. 3304(a)(1). Interested persons may identify their interest and capability to respond to the requirement or submit proposals. This notice of intent is not a request for competitive quotations; however, all quotations/responses received within seven (7) days of the issuance of this notice will be considered by the government. A determination by the government not to compete this proposed contract based upon responses to this notice is solely within the discretion of the government. Information received will normally be considered solely for the purpose of determining whether to conduct a competitive procurement. Any quotation/response should be emailed to Christina McMichael at wpn6@cdc.gov by 5:00 PM EST on August 15, 2023.